Medical misdiagnosis can have a profound effect on a person's quality of life. Endometriosis, a chronic condition that affects about 10% of women and people who menstruate, is often not diagnosed until seven years after symptoms begin. This condition is marked by the growth of tissue similar to the lining of the uterus outside the uterus, leading to severe pelvic pain, digestive issues, chronic fatigue, and fertility challenges. These symptoms can disrupt personal, professional, and family life significantly. Traditionally, diagnosing endometriosis has depended on medical imaging or surgery, both of which are difficult to interpret and not always accessible. Many people endure years of uncertainty due to the challenges in identifying small lesions. Menstrual blood, often viewed as a byproduct of the menstrual cycle, has emerged as a valuable source of biological information. Researchers from Inserm, the Pasteur Institute, the University of Claude Bernard Lyon 1, and the Léon-Bérard Center have explored this underutilized resource to improve the diagnosis of endometriosis. Menstrual blood contains intact uterine cells that naturally shed during the cycle. Collecting this fluid through a simple procedure provides a non-invasive way to analyze the condition of the uterine tissue, avoiding the need for painful examinations. This method offers a direct and less invasive way to understand the state of the uterus and its surrounding environment. The uterine cells found in menstrual blood reveal distinct biological markers. By comparing samples from people with endometriosis and those without, researchers found notable differences. Epithelial cells, which cover the surface of the uterine lining, showed the most significant changes in activity. These changes suggest disruptions in cellular function and communication with the immune system. The key advantage of this discovery is that these biological signals remain detectable in menstrual blood, eliminating the need to isolate and examine individual cell types in a laboratory. This simplifies the process of future medical testing and analysis. In response to these promising findings, the Pasteur Institute, Inserm, the CNRS, and the University of Paris Cité have filed a joint patent application to protect the research and encourage the development of future diagnostic tests. While these results are encouraging, the test is not yet available in medical settings. Further validation is needed on larger patient groups to confirm the stability of these biological markers across different menstrual cycles. Implementing this method in clinical practice will take additional time. Nonetheless, this research represents a major breakthrough in the management of endometriosis. By turning a natural, everyday fluid into a valuable diagnostic tool, science is moving toward a more compassionate, efficient, and responsive approach to women's health.